Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: estradiol dehydrogenase inhibitors - Forendo Pharma

Next Previous
Drug Profile

Research programme: estradiol dehydrogenase inhibitors - Forendo Pharma

Alternative Names: 17-beta hydroxysteroid dehydrogenase inhibitors; 17-β HSD type-1 inhibitors; 17β-HSD1 inhibitors; Dual HSD inhibitors; Estradiol dehydrogenase inhibitors; HSD inhibitors programme; HSD programme; HSD-1; HSD17B1 inhibitor

Latest Information Update: 20 Dec 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Hormos Medical; Solvay Pharmaceuticals; University of Turku
  • Developer Abbott Laboratories; QuatRx Pharmaceuticals
  • Class
  • Mechanism of Action Estradiol dehydrogenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Breast cancer; Endometriosis; Uterine leiomyoma

Most Recent Events

  • 13 Dec 2021 Forendo Pharma has been acquired by Organon
  • 28 Mar 2020 No recent reports of development identified for preclinical development in Endometriosis in Finland
  • 19 Mar 2018 Forendo Pharma plans a phase I trial for FOR 6219 in Endometriosis in second quarter of 2018
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top